Lajos Pusztai Selected Research

Lajos Pusztai Research Topics

Disease

235	Breast Neoplasms (Breast Cancer) 03/2022 - 04/2002
194	Neoplasms (Cancer) 11/2022 - 11/2002
46	Pathologic Complete Response 12/2021 - 06/2005
36	Triple Negative Breast Neoplasms 10/2022 - 03/2008
16	Residual Neoplasm 01/2022 - 04/2004
16	Neoplasm Metastasis (Metastasis) 01/2022 - 07/2004
6	Disease Progression 01/2020 - 03/2006
5	Carcinoma (Carcinomatosis) 10/2015 - 04/2004
3	Inflammatory Breast Neoplasms 11/2013 - 02/2011
2	Weight Loss (Weight Reduction) 03/2022 - 07/2018
2	Circulating Neoplastic Cells 01/2022 - 04/2009
2	Melanoma (Melanoma, Malignant) 10/2021 - 01/2012
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2004
2	Cardiotoxicity 07/2019 - 04/2018
2	Obesity 07/2018 - 07/2014

Drug/Important Bio-Agent (IBA)

55	Estrogen ReceptorsIBA 01/2022 - 03/2003
42	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2003
38	Hormones (Hormone)IBA 01/2022 - 09/2003
31	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 04/2003
29	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 02/2004
28	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2003
28	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 01/2003
27	Trastuzumab (Herceptin)FDA Link 11/2021 - 04/2002
22	AnthracyclinesIBA 12/2021 - 04/2004
19	human ERBB2 proteinIBA 01/2022 - 06/2005
18	RNA (Ribonucleic Acid)IBA 09/2021 - 06/2003
18	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 12/2006
18	Fluorouracil (Carac)FDA LinkGeneric 06/2018 - 04/2003
16	Pharmaceutical PreparationsIBA 01/2022 - 07/2004
16	Messenger RNA (mRNA)IBA 01/2022 - 06/2005
15	taxaneIBA 12/2021 - 08/2005
13	Biological ProductsIBA 10/2021 - 09/2006
11	ParaffinIBA 02/2021 - 01/2003
10	Epirubicin (Ellence)FDA LinkGeneric 10/2022 - 06/2005
10	ErbB Receptors (EGF Receptor)IBA 11/2020 - 04/2004
9	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
9	Estrogens (Estrogen)FDA Link 07/2021 - 07/2003
9	Tamoxifen FDA LinkGeneric 03/2018 - 04/2007
8	Lapatinib (GW572016)FDA Link 10/2021 - 11/2005
8	B7-H1 AntigenIBA 10/2021 - 05/2014
7	pembrolizumabIBA 10/2022 - 01/2016
7	durvalumabIBA 02/2022 - 10/2020
7	Formaldehyde (Formol)FDA Link 02/2021 - 05/2008
7	MicroRNAs (MicroRNA)IBA 02/2020 - 08/2010
7	Phenobarbital (Luminal)FDA Link 03/2018 - 08/2005
6	Monoclonal AntibodiesIBA 01/2019 - 04/2004
6	Progesterone Receptors (Progesterone Receptor)IBA 12/2015 - 03/2008
5	Tumor Biomarkers (Tumor Markers)IBA 10/2021 - 05/2008
5	Capecitabine (Xeloda)FDA Link 01/2021 - 09/2003
5	Phosphotransferases (Kinase)IBA 09/2015 - 11/2010
5	Docetaxel (Taxotere)FDA Link 11/2012 - 04/2002
4	130-nm albumin-bound paclitaxelIBA 02/2022 - 01/2018
4	Everolimus FDA Link 01/2022 - 07/2014
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2021 - 05/2014
4	Small Interfering RNA (siRNA)IBA 10/2019 - 11/2010
4	Transcription Factors (Transcription Factor)IBA 07/2018 - 09/2003
4	Investigational DrugsIBA 05/2018 - 07/2012
4	Taxoids (Taxanes)IBA 01/2017 - 07/2004
3	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 07/2016
3	CytokinesIBA 01/2022 - 02/2004
3	Epidermal Growth Factor (EGF)IBA 01/2022 - 08/2010
3	Metformin (Glucophage)FDA LinkGeneric 10/2021 - 08/2011
3	atezolizumabIBA 10/2021 - 01/2016
3	NucleotidesIBA 01/2021 - 01/2015
3	Ado-Trastuzumab EmtansineIBA 01/2021 - 10/2016
3	exemestane (Aromasin)FDA Link 01/2021 - 07/2015
3	Bevacizumab (Avastin)FDA Link 01/2020 - 10/2004
3	AntibodiesIBA 01/2016 - 07/2011
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2015 - 06/2005
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 05/2014 - 01/2008
3	Complementary DNA (cDNA)IBA 01/2006 - 03/2003
3	Peptide Hydrolases (Proteases)FDA Link 03/2004 - 03/2003
2	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2022 - 12/2015
2	Fulvestrant (Faslodex)FDA Link 01/2022 - 01/2018
2	Circulating Tumor DNAIBA 01/2022 - 01/2022
2	ChromatinIBA 01/2022 - 09/2020
2	CateninsIBA 01/2022 - 08/2010
2	Peptides (Polypeptides)IBA 10/2021 - 01/2008
2	N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA 02/2021 - 11/2020
2	LigandsIBA 01/2021 - 12/2009
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2020 - 01/2013
2	Keratins (Keratin)IBA 10/2020 - 01/2016
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2019 - 02/2012
2	Interleukin-8 (Interleukin 8)IBA 10/2019 - 01/2013
2	Matrix Metalloproteinase 9 (Gelatinase B)IBA 12/2018 - 11/2009
2	pertuzumabIBA 06/2018 - 10/2016
2	PlatinumIBA 01/2017 - 01/2015

Therapy/Procedure

110	Therapeutics 10/2022 - 04/2002
98	Drug Therapy (Chemotherapy) 10/2022 - 11/2002
71	Neoadjuvant Therapy 10/2022 - 11/2002
14	Adjuvant Chemotherapy 01/2020 - 02/2004
10	Immunotherapy 10/2021 - 01/2015
7	Segmental Mastectomy (Lumpectomy) 12/2017 - 10/2006
4	Mastectomy (Mammectomy) 12/2021 - 04/2011
4	Aftercare (After-Treatment) 09/2020 - 11/2002
4	Precision Medicine 12/2018 - 11/2006
3	Combination Drug Therapy (Combination Chemotherapy) 01/2012 - 01/2010
2	Radiotherapy 12/2017 - 08/2004
2	Chemoprevention 01/2016 - 01/2006